PureTech Health plc (PRTC.L)

182,60 -0,40 (-0,22%) Al cierre: 04:47PM BST

PureTech Health plc

6 Tide Street
Suite 400
Boston, MA 02210
United States
617 482 2333
https://www.puretechhealth.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 90

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Dr. Bharatt M. Chowrira J.D., Ph.D.	CEO & Executive Director	1,73M	N/A	1965
Ms. Daphne Zohar	Founder, Senior Advisor & Board Observer	3,15M	N/A	1971
Dr. Robert S. Langer Jr., Ph.D., ScD	Co-Founder & Non-Executive Director	106,74k	N/A	1949
Dr. Eric Elenko Ph.D.	Co-Founder & President	N/A	N/A	1973
Dr. David R. Elmaleh Ph.D.	Co-Founder & Senior Advisor	N/A	N/A	1948
Mr. Eric Green M.B.A.	Chief Operating Officer	N/A	N/A	N/A
Ms. Allison Mead Talbot	Head of Communications & Investor Relations	N/A	N/A	N/A
Mr. Charles Sherwood III, J.D., Ph.D.	General Counsel & Company Secretary	N/A	N/A	N/A
Mr. Spencer Ball	Senior Vice President of Human Resources	N/A	N/A	N/A
Ms. Aleksandra Filipovic M.D., Ph.D.	Head of Oncology	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en GBp.

Descripción

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Gobierno corporativo

El ISS Governance QualityScore de PureTech Health plc, a día 29 de junio de 2024, es 9. Las puntuaciones base son Auditoría: 10; Tablero: 3; Derechos de los accionistas: 1; Compensación: 10.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.